Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Am J Hematol. 2019 Feb 6;94(4):E112–E115. doi: 10.1002/ajh.25412

Figure 1. A. Effect of two starting doses of hydroxyurea on hematology measures.

Figure 1.

Shown are mean and SD values for hemoglobin, MCV, neutrophils and platelets over the first 12 to 14 weeks of hydroxyurea treatment in the Multicenter Study of Hydroxyurea (MSH) cohort (14 weeks of treatment, 15 mg/kg/day, n=152)_ENREF 213 and the Ibadan cohort (12 weeks of treatment, 10 mg/kg/day, n=38). Changes from baseline were comparable between the two approaches in hemoglobin, MCV and platelets but the neutrophils had less of a decline in the Ibadan cohort. B. Effect of two approaches to hydroxyurea dosing on end of study values for hemoglobin F and hematology measures.At end of study, changes in hemoglobin F and other hematology measures were comparable between the MSH study, which targeted “maximum tolerated dose” hydroxyurea, and the Ibadan study, which administered 500 mg/day (10 mg/kg/day) as a “fixed low-dose” regimen. Hb F (hemoglobin F), HB (hemoglobin), HCT (hematocrit), MCV (mean corpuscular volume), WBC (white blood cells), ANC (neutrophils), PLT (platelets).